Paper examines R&D funding for diseases of poverty
The Global Health Technologies Coalition (GHTC) today released a new paper that provides unique insight into the funding landscape for global health research and development (R&D). The paper examines key financing challenges and opportunities facing organizations that advance the development of new vaccines, drugs, diagnostics, microbicides, and other health products for low- and middle-income countries (LMICs).
The paper focuses on nonprofit product development organizations (NPPDs), or nongovernmental organizations that partner with the public, philanthropic, and private sectors to develop health products specifically targeted for HIV/AIDS, tuberculosis, malaria, neglected tropical diseases, maternal health, and other needs in LMICs. Previous research has found that NPPDs play a vital role in bringing together the fragmented resources and expertise of the various sectors involved in neglected disease R&D.
The new GHTC paper finds that the funding landscape for NPPDs has shifted in recent years, with donors from the public and private sectors reducing their overall investments in product development for LMICs. For instance, funding for NPPDs has seen a decrease of $50 million per year since 2009. The paper identifies four main funding challenges facing NPPDs in this changing funding environment:
- The small number of major funders means that NPPDs cannot keep pace with the increased costs of progressing new health products through
large-scale studies. As a result, funding available to NPPDs is shrinking just as promising products are advancing through the research pipeline.
- Donors are increasingly awarding project-specific funding, which can only be used for a designated activity, as opposed to core funding
that gives NPPDs the ability to support multiple projects at different stages of development. Because of this shift, NPPDs noted that funding can
significantly influence scientific decision making.
- As some funders scale back on their support, NPPDs are increasingly seeking out multiple donors and funding sources. While funding diversification
can help provide independence, it can result in discordant funder priorities and requirements. NPPDs with varied funding sources
can experience challenges in managing multiple funder requirements and gaps in funding. As NPPDs seek out new funding opportunities, they must
invest in developing new skill sets—including managing, identifying, and cultivating new sources of support. This involves dedicating additional
staff time, sometimes from researchers, and establishing new systems to cultivate new donor relationships.
Fortunately, the paper also finds that NPPDs are adapting in this new funding environment. For instance, many NPPDs are developing approaches to address
these financing challenges, such as forming new partnerships and exploring innovative financing to sustain progress.
The paper also provides a set of criteria that donors, NPPDs, and others can use to evaluate and better coordinate global health R&D funding opportunities. According to the paper, funding mechanisms and donor support must:
- Support a portfolio of products at different stages of development. This ensures that only the most promising products advance through
the research pipeline and allows NPPDs to shift funds to more promising projects.
- Provide sustainable funding commitments. Additionally, the duration of funding commitments should be guided by the scientific need.
This will require multi-year funding commitments that align with the timelines of the product development process.
- Support core activities. These activities are critical to the success of any organization. All funding should include a proportionate
level of support for the overall costs of running the organization or specific program.
- Incentivize new investment. Funding is most effective when it can be used to attract new financial support and other investments.
This paper—Financing and Coordination of Health Research: Perspectives from Nonprofits on Accelerating Product Development and Improving Access for Low- and Middle-Income Countries, Volume 2—is the second in a series from the GHTC that examines financing, accessibility, regulatory, and capacity issues facing NPPDs. The series aims to inform global policy and financing discussions about R&D for neglected and poverty-related diseases affecting LMICs.